OBD
NEUTRALOxford BioDynamics Plc Announces Holding Change
The healthcare diagnostics company has announced a change in shareholding, with Trafalgar Trading Fund Inc increasing its stake.
Oxf BioDynamics
0.4500GBX
5.88%
Market Cap
8.81M
Volume
25.83k
0% of avg
P/E Ratio
-15.00
EPS (TTM)
-0.03
Beta
-0.47
Day Range
0.0000p - 0.0000p
52 Week Range
0.0000p0.4500p4.2500p
0.4500p
Upcoming Events
Q4 2025
Projected depletion of current cash reserves
High Impact Event
Q1 2026
Potential Commercialization of CRC Test (Q1 2026)
High Impact Event
OBD
NEUTRALOxford BioDynamics Publishes Positive Data on EpiSwitch CiRT Test
The healthcare company has published positive results from a clinical study of its EpiSwitch CiRT test, which predicts patient response to immunotherapy.
OBD
NEUTRALOxford BioDynamics Collaborates with Google Cloud to Accelerate Precision Medicine Analytics
The biotechnology company has agreed to collaborate with Google Cloud to support the development and deployment of its analytical framework on the cloud, aiming to scale its 3D genomic analytics capabilities.
OBD
NEUTRALOxford BioDynamics Announces Holding Change
The healthcare diagnostics company has announced a change in shareholding, with Trafalgar Trading Fund Inc acquiring a 3.3% stake through CFDs.
OBD
NEUTRALOxford BioDynamics to Present EpiSwitch Platform at Agilent-Sponsored Webinar
The biotechnology company is set to present its EpiSwitch 3D genomics platform at a webinar hosted by GenomeWeb and sponsored by Agilent Technologies.
OBD
NEUTRALOxford BioDynamics Plc Provides Regulatory Update
The healthcare diagnostics company has filed a regulatory update regarding a change in shareholding.
OBD
NEUTRALOxford BioDynamics Announces Holding Change
The healthcare diagnostics company has announced a change in shareholding, with Spreadex Ltd increasing its stake in the company.
OBD
NEUTRALOxford BioDynamics Announces Successful Pfizer Study on EpiSwitch Biomarkers
The healthcare company announces that Pfizer has published positive results on the use of its EpiSwitch biomarkers in evaluating tumour status and treatment outcomes.
OBD
NEUTRALOxford BioDynamics Announces Major Shareholding Change
The biotechnology company has reported a change in major shareholding, with Spreadex LTD now holding a 2.95% stake in the company.
OBD
BADOxford BioDynamics Reports Increased Revenue but Faces Cash Constraints in H1 2025
The diagnostics firm reported increased revenue but faces significant cash constraints and going concern issues. Plans to 'right-size' the business signal challenging times ahead.